B

한국유니온제약

080720KOSDAQ

58.0 / 100

Reference Date: 2026-10-23

Financial Score26.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Union Pharmaceutical focuses on manufacturing and selling specialty pharmaceuticals, exporting finished drugs, and providing CMO (contract manufacturing) services. The company specializes in antibiotics, cardiovascular, and musculoskeletal products, leveraging its GMP facilities and R&D efforts to enhance profitability. It has expanded exports to regions such as the Middle East, Southeast Asia, and South America, and is further expanding its CMO business and product portfolio through a newly completed factory.

Number of Employees

123people

Average Salary

39.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
419.43Industry Average 8.007.0Point

52.4x industry avg (excellent)

Debt Ratio
-21.02Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼23.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼92.6% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 88.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,410Won52-week high 2,72552-week low 2,410
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 1Neutral 4Negative 0
  • Neutral주요사항보고서(감자결정)2026-10-21
  • Positive주요사항보고서(유상증자결정)2026-10-21
  • Neutral[기재정정]반기보고서 (2026.06)2026-10-12
  • Neutral상호변경안내2026-10-08
  • Neutral임시주주총회결과2026-10-08